Serum Chairman Says Company Held Early Merger Talks With Cipla
This article is for subscribers only.
Serum Institute of India Ltd., Asia’s largest vaccine maker, held preliminary discussions with generic drugmaker Cipla Ltd. on a merger, Chairman Cyrus Poonawalla said.
While Serum could never go up for sale, there is a small chance that it could merge with a company like Cipla, Poonawalla told CNBC-TV18 in a broadcast interview. Asked whether there there had been talks with Cipla, Poonawalla said there had been “a little bit,” according to a video clip posted on the television channel’s website.